Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.49 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.43 |
| ▸ | FEN1 | P39748 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1141606 | 1.00 | HCRTR1 (0.49) | HCRTR1HCRTR2KMT2APOLBGFER | |
| SCHEMBL269121 | 0.90 | POLB (0.48) | HCRTR1KMT2APOLBGFERALOX5AP | |
| SCHEMBL269120 | 0.90 | POLB (0.48) | HCRTR1KMT2APOLBGFERALOX5AP | |
| SCHEMBL1838881 | 0.86 | KMT2A (0.45) | HCRTR1KMT2APOLBGFER | |
| SCHEMBL1141278 | 0.84 | CCNK (0.44) | HCRTR1HCRTR2KMT2AALOX5APFEN1 | |
| SCHEMBL1141276 | 0.84 | CCNK (0.44) | HCRTR1HCRTR2KMT2AALOX5APFEN1 | |
| SCHEMBL1838142 | 0.83 | CCNK (0.47) | — | |
| SCHEMBL1141649 | 0.82 | GFER (0.49) | HCRTR1HCRTR2KMT2APOLBGFER | |
| SCHEMBL1141644 | 0.82 | GFER (0.49) | HCRTR1HCRTR2KMT2APOLBGFER | |
| SCHEMBL1838876 | 0.81 | EGFR (0.44) | HCRTR1KMT2APOLBGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | claimed |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | claimed |
| EP-2318367-B1 | PIPERIDINE AND PYRROLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039857-A1 | PIPERIDINE AND PYROOLIDINE COMPOUNDS | HCRTR1, HCRTR2, NPY1R | HCRTR1 1/4885HCRTR2 2/4885KMT2A 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.